Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR5662(2)] to Nuclear Matrix Protein p84
- Suitable for: ICC/IF, WB, IHC-P, Flow Cyt
- Reacts with: Mouse, Rat, Human
Product nameAnti-Nuclear Matrix Protein p84 antibody [EPR5662(2)]
See all Nuclear Matrix Protein p84 primary antibodies
DescriptionRabbit monoclonal [EPR5662(2)] to Nuclear Matrix Protein p84
Tested applicationsSuitable for: ICC/IF, WB, IHC-P, Flow Cytmore details
Unsuitable for: IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human Nuclear Matrix Protein p84 aa 350-450. The exact sequence is proprietary.
- WB: HeLa, U-87 MG, 293T and HepG2 (ab7900) cell lysates. IHC-P: Human breast carcinoma tissue. ICC/IF: HeLa cells. Flow Cyt: HeLa cells.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab131268 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Detects a band of approximately 84 kDa (predicted molecular weight: 76 kDa).|
|IHC-P||1/50 - 1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. (Heat to 98°C, allow to cool for 10-20 minutes)|
FunctionComponent of the THO subcomplex of the TREX complex. The TREX complex specifically associates with spliced mRNA and not with unspliced pre-mRNA. It is recruited to spliced mRNAs by a transcription-independent mechanism. Binds to mRNA upstream of the exon-junction complex (EJC) and is recruited in a splicing- and cap-dependent manner to a region near the 5' end of the mRNA where it functions in mRNA export. The recruitment occurs via an interaction between THOC4 and the cap-binding protein NCBP1. DDX39B functions as a bridge between THOC4 and the THO complex. The TREX complex is essential for the export of Kaposi's sarcoma-associated herpesvirus (KSHV) intronless mRNAs and infectious virus production. The recruitment of the TREX complex to the intronless viral mRNA occurs via an interaction between KSHV ORF57 protein and THOC4.
Regulates transcriptional elongation of a subset of genes. Participates in an apoptotic pathway which is characterized by activation of caspase-6, increases in the expression of BAK1 and BCL2L1 and activation of NF-kappa-B. This pathway does not require p53/TP53, nor does the presence of p53/TP53 affect the efficiency of cell killing. Activates a G2/M cell cycle checkpoint prior to the onset of apoptosis. Apoptosis is inhibited by association with RB1.
Tissue specificityUbiquitous. Expressed in various cancer cell lines. Expressed at very low levels in normal breast epithelial cells and highly expressed in breast tumors. Expression is strongly associated with an aggressive phenotype of breast tumors and expression correlates with tumor size and the metastatic state of the tumor progression.
Sequence similaritiesContains 1 death domain.
DomainAn intact death domain is needed for apoptosis.
modificationsExpression is altered specifically during apoptosis and is accompanied by the appearance of novel forms with smaller apparent molecular mass.
Cellular localizationCytoplasm and Nucleus speckle. Nucleus > nucleoplasm. Nucleus matrix. Cytoplasm. Can shuttle between the nucleus and cytoplasm. Nuclear localization is required for induction of apoptotic cell death. Translocates to the cytoplasm during the early phase of apoptosis execution.
- Information by UniProt
FormNuclear (Isoform 1) and Cytoplasmic (Isoform 1 and 2).
- hTREX84 antibody
- Death domain containing protein p84N5 antibody
- HPR 1 antibody
All lanes : Anti-Nuclear Matrix Protein p84 antibody [EPR5662(2)] (ab131268) at 1/10000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : U-87 MG cell lysate
Lane 3 : 293T cell lysate
Lane 4 : HepG2 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-Rabbit HRP at 1/2000 dilution
Predicted band size: 76 kDa
Immunofluorescent staining of HeLa cells labelling Nuclear Matrix Protein p84 with ab131268 at 1/100 dilution.
Immunohistochemical analysis of paraffin embedded human breast carcinoma tissue labeling Nuclear Matrix Protein p84 with ab131268 at 1/50 dilution.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Flow Cytometry analysis of HeLa (human cervix adenocarcinoma) cells labeling Nuclear Matrix Protein p84 with purified ab131268 at 1/120 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488)(1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) were used as the unlabeled control.
ab131268 has been referenced in 7 publications.
- Núñez KG et al. Interleukin-33 / Cyclin D1 imbalance in severe liver steatosis predicts susceptibility to ischemia reperfusion injury. PLoS One 14:e0216242 (2019). PubMed: 31034519
- Song XL et al. miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3ß. Biomed Pharmacother 99:369-374 (2018). WB, RT-PCR . PubMed: 29358129
- Chen Z et al. Loss of Fezf2 promotes malignant progression of bladder cancer by regulating the NF-?B signaling pathway. Lab Invest 98:1225-1236 (2018). PubMed: 29925938
- Chen Z et al. HBO1 promotes cell proliferation in bladder cancer via activation of Wnt/ß-catenin signaling. Mol Carcinog 57:12-21 (2018). PubMed: 28796367
- Yang R et al. LASP2 suppressed malignancy and Wnt/ß-catenin signaling pathway activation in bladder cancer. Exp Ther Med 16:5215-5223 (2018). PubMed: 30542477
- Zhao L et al. DDX3X promotes the biogenesis of a subset of miRNAs and the potential roles they played in cancer development. Sci Rep 6:32739 (2016). IP . PubMed: 27586307
- Bachran C et al. Cytolethal distending toxin B as a cell-killing component of tumor-targeted anthrax toxin fusion proteins. Cell Death Dis 5:e1003 (2014). WB ; Human . PubMed: 24434511